Last reviewed · How we verify

Tripterygium glycosides

Zhu Weiming · Phase 1 active Small molecule Quality 3/100

Tripterygium glycosides is a Small molecule drug developed by Zhu Weiming. It is currently in Phase 1 development. Also known as: TW.

At a glance

Generic nameTripterygium glycosides
Also known asTW
SponsorZhu Weiming
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tripterygium glycosides

What is Tripterygium glycosides?

Tripterygium glycosides is a Small molecule drug developed by Zhu Weiming.

Who makes Tripterygium glycosides?

Tripterygium glycosides is developed by Zhu Weiming (see full Zhu Weiming pipeline at /company/zhu-weiming).

Is Tripterygium glycosides also known as anything else?

Tripterygium glycosides is also known as TW.

What development phase is Tripterygium glycosides in?

Tripterygium glycosides is in Phase 1.

Related